

## **Samsung BioLogics, CDMO and Beyond**

Yonghwan Jin, Ph.D.

VP, Head of Drug Product Department, Manufacturing Center

Samsung BioLogics was established in April 2011, and is headquartered in Incheon, South Korea.

As a joint venture between Samsung affiliate companies and Quintiles Transnational Corp., Samsung BioLogics aims to become a global leader in the biopharmaceutical manufacturing industry.

Samsung has a long, rich history of research and development work. Our biologics business builds on principles of our past achievements and brings our technological leadership to the biologics sector. With Samsung's quality, technology and innovation, Samsung BioLogics will establish a new global standard for best practices within biopharmaceutical manufacturing and transform global healthcare as we know it.

We are committed to excellence in the development and manufacturing of bio-healthcare products. Our client-oriented business model encourages high-standard, fast-turnaround contract manufacturing partnerships. Furthermore, our state-of-the-art advanced facilities are fully compliant with global healthcare regulations and Current Good Manufacturing Practice (cGMP) standards. To better serve the patients of our partners, we provide the proper infrastructure to develop, refine, and distribute biopharmaceutical products worldwide.